BAIYUNSHAN PH Subsidiary Obtains Drug Registration Certificate for Cefaclor Sustained-Release Tablets (II)
Stock News
Jun 10
The pharmaceutical subsidiary of BAIYUNSHAN PH (600332.SH) has been granted a drug registration certificate by the National Medical Products Administration.
The certificate pertains to Cefaclor Sustained-Release Tablets (II), a second-generation cephalosporin antibiotic.
This medication is clinically indicated for treating infections caused by susceptible pathogenic bacteria, including acute bronchitis, acute exacerbations of chronic bronchitis, pharyngitis, tonsillitis, pneumonia, sinusitis, uncomplicated lower urinary tract infections, and skin and soft tissue infections.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.